
ImmuCell Corporation: updates and filings
Price
$11.25
November 18, 2026Market cap $102M
What Ploutos Investor adds for ImmuCell
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 13, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Results of operationsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Shares registered for employeesFormS-8
- Oct 13, 2026Results of operationsForm8-K
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jul 9, 2026Results of operationsForm8-K
- Jun 17, 2026Shareholder voteForm8-K
- Jun 10, 2026Regulation FD disclosureForm8-K
- May 14, 2026Results of operationsForm8-K
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 13, 2026Annual report (amendment)for the period to Dec 31, 2025Form10-K/A
- May 8, 2026Material agreement enteredForm8-K
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Apr 14, 2026Preliminary proxy statementFormPRE 14A
- Apr 14, 2026Officer or director change, other material eventsForm8-K
- Apr 8, 2026Results of operationsForm8-K
- Mar 30, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 18, 2026Officer or director changeForm8-K
- Mar 4, 2026Results of operationsForm8-K
- Feb 9, 2026Officer or director changeForm8-K
- Feb 2, 2026Material agreement entered, officer or director changeForm8-K
- Jan 8, 2026Results of operations, material impairment, other material eventsForm8-K
- Dec 29, 2025Material impairment, other material eventsForm8-K
- Nov 20, 2025Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | S-8 | Shares registered for employees | Document |
| Oct 13, 2026 | 8-K | Results of operations | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jul 9, 2026 | 8-K | Results of operations | Document |
| Jun 17, 2026 | 8-K | Shareholder vote | Document |
| Jun 10, 2026 | 8-K | Regulation FD disclosure | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 13, 2026 | 10-K/A | Annual report (amendment)for the period to Dec 31, 2025 | Document |
| May 8, 2026 | 8-K | Material agreement entered | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 14, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Apr 14, 2026 | 8-K | Officer or director change, other material events | Document |
| Apr 8, 2026 | 8-K | Results of operations | Document |
| Mar 30, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 18, 2026 | 8-K | Officer or director change | Document |
| Mar 4, 2026 | 8-K | Results of operations | Document |
| Feb 9, 2026 | 8-K | Officer or director change | Document |
| Feb 2, 2026 | 8-K | Material agreement entered, officer or director change | Document |
| Jan 8, 2026 | 8-K | Results of operations, material impairment, other material events | Document |
| Dec 29, 2025 | 8-K | Material impairment, other material events | Document |
| Nov 20, 2025 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 3, 1995.
The full analysis
What do ImmuCell's filings show?
The filings are where every one of ImmuCell's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.